The U.S. Patent and Trademark Office issued U.S. patent No. 10,612,042, which covers the company's approach for delivering a payload, such as a protein or nucleic acid, across a plasma membrane of a cell.

Avectas is developing the delivery platform designed for the ex vivo manufacture of gene-modified cell therapy products. Its Solupore cell engineering technology is designed to overcome the challenges of manufacturing autologous and allogeneic cellular therapy products.

In March, Avectas announced a collaboration with Vycellix to develop technology for the optimized manufacture of cell and gene therapies. In February, Avectas signed a collaboration agreement with the Centre for Commercialization of Regenerative Medicine in Toronto to bring its Solupore nonviral cell engineering platform into the clinic.